Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
Month
1
2
3
4
5
6
7
8
9
10
11
12
2024.08.28
Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million
2024.08.05
Boan’s Dulaglutide Cleared by FDA for Clinical Trials
2024.07.26
First in China: Boan Biotech’s Novel Investigational CD228-Directed ADC Approved for Clinical Trials
17
2024-07
BLA for Boan Biotech’s BA9101 (Aflibercept) Accepted in China
28
2024-05
First in China: BLA for Boan’s Dulaglutide Injection Accepted
27
2024-05
Boan’s Boluojia® (Denosumab) Approved for Marketing in China
08
2024-04
Boan Biotech Completes Phase 3 Clinical Trial for Its Aflibercept intravitreous Injection BA9101 in China, Planning to file a BLA
26
2024-03
Boan Biotech Announces 2023 Financial Results
08
2024-03
Phase 3 Clinical Trial Completed in China for Boan Biotech’s Dulaglutide Injection BA5101. BLA to be filed soon
30
2024-01
Boan Biotech Authorizes Zencore Biologics to Use Its BA-HIEXcell® Stable Cell Line Development Platform
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
